### Subject Index

Acanthosis nigricans, diabetes association 11, 12

Acarbose  
- effects of treatment 99, 100  
- efficacy 10  
- α-glucosidase inhibition 99  
- side effects 100, 101

α-cell, glucose threshold 21

Acetoehexamide, characteristics 31

Acetylcholine, insulin secretion regulation 24

Acupuncture, neuropathy treatment 206

Advanced glycation end-products  
- binding sites 126, 127  
- diabetic nephropathy role 125–128  
- inhibitors 127, 128  
- reactions in formation 125, 126

Alcohol, restriction 66

Allergy, insulin therapy reaction 87

Alprostadil, erectile dysfunction treatment 227

Alström syndrome, diabetes association 12

Aminoguanidine, advanced glycation end-product inhibition 127

Amitriptyline, neuropathy treatment 206

Amylin  
- diabetes therapy 96  
- physiological actions 95, 96

Anamnesis, erectile dysfunction diagnosis 223, 224

Angioplasty  
- outcomes in diabetes 190, 191  
- restenosis prevention 195

Angiotensin-converting enzyme inhibitors  
- diabetic nephropathy management 130  
- heart failure management in diabetes 196  
- hypertension management with nephropathy 154, 155, 162–170, 237  
- myocardial infarction management in diabetes 193, 194  
- retinopathy prevention 142

Apolipoproteins  
- diabetes mellitus abnormalities  
  - overview 178  
  - type 1 diabetes 178, 179  
  - type 2 diabetes 179–181

- lipid-lowering intervention in diabetes  
  - cardiovascular disease effects 181, 182  
  - dietary modification 182  
  - drug therapy  
    - fibrates 182–184  
    - statins 182–184  
    - guidelines for treatment 182, 184  
    - normal metabolism 174–178

Aspartame, safety 68

Aspirin  
- myocardial infarction management in diabetes 192, 193  
- prevention trials in diabetes 237, 238

Ataxia telangiectasia, diabetes association 12
β-blockers
heart failure management in diabetes 196
hypertension management in diabetes 162, 163
myocardial infarction management in diabetes 193
Blood flow, insulin resistance role 49, 50
Blood pressure, see Hypertension
Body mass index
fat distribution and health risks 57, 58
ideal values 57
β-cell, glucose threshold 21
Calcium channel blockers
hypertension management in diabetes 54, 162, 163
myocardial infarction management in diabetes 194
Caloric intake, see Diet
Capsaicin, neuropathy treatment 206
Carbamazepine, neuropathy treatment 206
Carbohydrate, dietary 59–62
Cardiovascular disease
acronyms for diabetes studies 187
aspirin prevention trials in diabetes 237, 238
clinical manifestations in diabetes
angioleptin and bypass grafting outcomes 190, 191
heart failure 191
myocardial infarction 188, 189
unstable angina 190
diabetes risks 186
heart failure management in diabetes
angiotensin-converting enzyme inhibitors 196
β-blockers 196
lipid-lowering intervention effects in diabetes 181, 182
multifactorial treatment approach 229
myocardial infarction management in diabetes
angiotensin-converting enzyme inhibitors 193, 194
aspirin 192, 193
β-blockers 193
calcium channel blockers 194
fibrinolytic agents 192
insulin-glucose infusion 191, 192
platelet inhibitors 193
statins 194
myocardial ischemia treatment in diabetes 194, 195
natural history in diabetes 188
pathophysiology in diabetes 186, 188
prognosis in diabetes 196, 197
restenosis prevention following angioplasty or bypass surgery 195
Cataract, diabetic 135
Charcot neuroarthropathy, see Foot problems, diabetes
Cholecystokinin, insulin secretion regulation 24
Cholesterol, dietary 62, 63
Clorpropamide, characteristics 30, 31
Coronary artery bypass grafting
outcomes in diabetes 190, 191
restenosis prevention 195
Desipramine, neuropathy treatment 206
Diabetes Control and Complication Trial, outcomes of hyperglycemia control 90, 91
Diabetes type 1, see Type 1 diabetes
Diabetes type 2, see Type 2 diabetes
Diabetic foot, see Foot problems, diabetes
Diabetic gastropathy, gestational diabetes mellitus 248
Diabetic ketoacidosis
clinical presentation 104
complications 106
diagnosis 106, 107
hormone roles 103
laboratory data 105, 106
mortality 106
pathophysiology 103, 104
treatment
antibiotics 108
bicarbonate 108
insulin 107
potassium 108
Diabetic nephropathy
classification 200
clinical features
autonomic neuropathies 202
cranial mononeuropathies 201
diabetic amyotrophy 202
isolated and multiple
mononeuropathies 201
peripheral sensory neuropathies
202, 203
truncal mononeuropathy 201
definition 199, 200
diagnosis 204, 205
epidemiology 200, 201
foot, see Foot problems, diabetes
gestational diabetes mellitus 249
natural history 199
screening 204
treatment
drugs 206, 207
stage-specific management 205, 206

Diabetic retinopathy
blindness incidence 135
clinical appearance
diabetic maculopathy 140, 141
erly changes 136
proliferative diabetic retinopathy
137–139
diagnosis
fluorescein angiography 145, 146
optical coherence tomography 146
ultrasound 147
epidemiology 141
gestational diabetes mellitus 142, 248, 249
nomenclature 136
prevention 141, 142, 151
psychosocial aspects 150
screening
costs 145
interval for screening 145
ocular background examination
143, 144
organization of screening programs 144, 145
rationale 142
visual acuity testing 144
treatment
retinal photocoagulation
  exudative diabetic maculopathy 148, 149
  indications 146, 147
  neovascular glaucoma 149
  principle 147
  proliferative diabetic retinopathy 147, 148
  vitrectomy 149

etiology in diabetes 218–220
etiopathogenesis in diabetes
  endothelial alterations 222
  hormonal alterations 222, 223
  impaired glucose metabolism 221
  neurological alterations 222
  overview 220
  psychological factors 220, 221
  vascular alterations 221
spermatogenesis alterations in diabetes 223
treatment
  alprostadil 227
  doxazosin 225, 226
  external mechanical support 227, 228
  intracavernosal injection 227
  nitroglycerin 226
  penile prosthesis 228
  psychotherapy 225
  revascularization surgery 228
  sildenafil 226, 227
  yohimbine 225, 226

Diet
alcohol 66
caloric requirements 58–60
caloric restriction in obese type 2 diabetes
diet components 68, 69
  effects 56, 57
  carbohydrate 59–62
  compliance 70
dyslipidemia treatment 236
  exercise prescription 69
  fat 62, 63
  fiber 64–66
gestational diabetes mellitus management 243
goals of therapy 56
hyperglycemia control benefits 230
  protein 63, 64
  sodium 66
  sweeteners 66–68
Doxazosin, erectile dysfunction treatment 225, 226
Dyslipidemia, see also Apolipoproteins,
  High-density lipoprotein, Low-density lipoprotein, Very low-density lipoprotein
treatment and diabetes progression 235, 236
diet 236
  exercise 236
  fibrates 236
  statins 236
edema, insulin therapy reaction 85
Endothelin, diabetic nephropathy role 131
Epinephrine, insulin secretion regulation 24
Erectile dysfunction
diagnosis 223–225
Fasting plasma glucose
diabetes diagnosis 14, 15, 19
  reliability 16
Fat, dietary 62, 63, 182
Fiber, dietary 64–66
Fibrates
treatment 236
  lipid-lowering intervention 182–184
Fibrocalculous pancreatopathy, diabetes
  association 12
Foot problems, diabetes
Charcot neuroarthropathy 215, 216
neuropathy, see also Diabetic neuropathy
  autonomic neuropathy 210
  somatic neuropathy 209, 210
  overview 208
  peripheral vascular disease 208, 209

Subject Index
Foot problems, diabetes (continued)
ulcers
behavioral/psychological factors 212
biomechanical aspects 210, 211
cardiovascular factors 212
education of patients 213, 214, 216
gender differences 211, 212
glycemic control and prevention 211
infection 214
management 213–215
microcirculation and endothelial
dysfunction 212, 213
prevention 213
recurrence 211
retinopathy and nephropathy
association 211
wound healing 212

Free fatty acid
gestational diabetes mellitus pathogenesis
role 241
insulin secretion regulation 22, 28
metabolism in insulin resistance 46–48
Fructosamine, insulin therapy monitoring
84
Fructose, dietary 67

Gabapentin, neuropathy treatment 206
Gastric inhibitory polypeptide, insulin
secretion regulation 24
Gestational diabetes mellitus complications
gastropathy 248
nephropathy 249
neuropathy 249
overview 12, 13, 242
retinopathy 142, 248, 249
diabetes progression following pregnancy
243, 244
diagnosis 15, 19, 243, 244
fetal effects
congenital anomalies 246–248
demise 249
fetal macrosomia 248
intrauterine growth restriction 248
management
diet 243
insulin therapy 244, 246, 252

HBA1c
insulin therapy monitoring 84
monitoring of metabolic control 18
Heart failure
diabetes association and presentation 191
management in diabetes
angiotensin-converting enzyme
inhibitors 196
β-blockers 196
Hemoglobin, glycated, see HBA1c
High-density lipoprotein
diabetes mellitus abnormalities
overview 178
type 1 diabetes 178, 179
type 2 diabetes 179–181
lipid-lowering intervention in diabetes
cardiovascular disease effects 181, 182
dietary modification 182
drug therapy
fibrates 182–184
Statins 182–184

Glibenclamide, characteristics 31
Gliclazide, characteristics 31
Glipizide, characteristics 31
Gliquidone, characteristics 31, 32
Glucagon, insulin secretion regulation
24, 25
Glucagon-like peptide-1
insulin secretion regulation 24, 28, 36
therapeutic application 36
Glucokinase
glucose sensing 21, 22
MODY-2 mutations 10, 11, 22

Glucometer, insulin therapy monitoring
84
Glycated hemoglobin, see HBA1c
Glycemic index, foods 61
Glycosuria, monitoring of diabetic control
18

Glucose
insulin secretion regulation 20–22
metabolism in type 2 diabetes 46–48
Gliburide, characteristics 31

Gestational diabetes mellitus
diabetes association and presentation 191
complications
gastropathy 248
management in diabetes

diagnosis 15, 19, 243, 244

General symptoms

1. Painful
2. Burning
3. Numbness
4. Swelling

Foot problems, diabetes (continued)
ulcers
behavioral/psychological factors 212
biomechanical aspects 210, 211
cardiovascular factors 212
education of patients 213, 214, 216
gender differences 211, 212
glycemic control and prevention 211
infection 214
management 213–215
microcirculation and endothelial
dysfunction 212, 213
prevention 213
recurrence 211
retinopathy and nephropathy
association 211
wound healing 212

Free fatty acid
gestational diabetes mellitus pathogenesis
role 241
insulin secretion regulation 22, 28
metabolism in insulin resistance 46–48
Fructosamine, insulin therapy monitoring
84
Fructose, dietary 67

Gabapentin, neuropathy treatment 206
Gastric inhibitory polypeptide, insulin
secretion regulation 24
Gestational diabetes mellitus complications
gastropathy 248
nephropathy 249
neuropathy 249
overview 12, 13, 242
retinopathy 142, 248, 249
diabetes progression following pregnancy
243, 244
diagnosis 15, 19, 243, 244
fetal effects
congenital anomalies 246–248
demise 249
fetal macrosomia 248
intrauterine growth restriction 248
management
diet 243
insulin therapy 244, 246, 252

HBA1c
insulin therapy monitoring 84
monitoring of metabolic control 18
Heart failure
diabetes association and presentation 191
management in diabetes
angiotensin-converting enzyme
inhibitors 196
β-blockers 196
Hemoglobin, glycated, see HBA1c
High-density lipoprotein
diabetes mellitus abnormalities
overview 178
type 1 diabetes 178, 179
type 2 diabetes 179–181
lipid-lowering intervention in diabetes
cardiovascular disease effects 181, 182
dietary modification 182
drug therapy
fibrates 182–184
Statins 182–184

Glibenclamide, characteristics 31
Gliclazide, characteristics 31
Glipizide, characteristics 31
Gliquidone, characteristics 31, 32
Glucagon, insulin secretion regulation
24, 25
Glucagon-like peptide-1
insulin secretion regulation 24, 28, 36
therapeutic application 36
Glucokinase
glucose sensing 21, 22
MODY-2 mutations 10, 11, 22

Glucometer, insulin therapy monitoring
84
Glycated hemoglobin, see HBA1c
Glycemic index, foods 61
Glycosuria, monitoring of diabetic control
18

Glucose
insulin secretion regulation 20–22
metabolism in type 2 diabetes 46–48
Gliburide, characteristics 31

Gestational diabetes mellitus
diabetes association and presentation 191
complications
gastropathy 248
management in diabetes

diagnosis 15, 19, 243, 244

General symptoms

1. Painful
2. Burning
3. Numbness
4. Swelling
guidelines for treatment 182, 184
normal metabolism 174–178
HMG-CoA reductase inhibitors, lipid-lowering intervention 182–184
Hyperbaric oxygen therapy, foot ulcer treatment 215
Hyperglycemia
c Control and diabetes progression 1, 229–232
treatment
diet 230
exercise 230
insulin 231
metformin 230, 231
sulfonylureas 230, 231
type 1 diabetes pathophysiology 6, 7
Hyperosmolar nonketotic syndrome
c Clinical presentation 108
laboratory findings 109
mortality 108
pathophysiology 109
treatment 109, 110
Hypertension
c Comparison between diabetes types 152
c Control and diabetes progression 232, 233, 235
diabetic nephropathy patients
arterial disease 161, 162
glomerular filtration rate fall in type 1 diabetes 158–160
kidney damage role and indicator 153, 154, 156, 157, 160
microalbuminuria 157, 158, 171
pathogenesis 162
sodium retention 161
treatment
angiotensin-converting enzyme inhibitor management 154, 155, 162–170
diet 168, 172
guidelines 169–171
microalbuminuria patients 165, 166
normoalbuminuria 164, 165
overt diabetic nephropathy patients 167, 168
United Kingdom Prospective Diabetes Study outcomes 91, 92, 169
treatment
angiotensin-converting enzyme inhibitors 162–164
- blockers 162, 163
calcium channel blockers 162, 163
diuretics 162, 163
glycemic control in treatment 164
Hypoglycemia
c Classification
causes of hypoglycemia 113
fasting hypoglycemia
factitious hypoglycemia 115
increased glucose utilization 114, 115
reduced glucose production 113, 114
postprandial hypoglycemia, forms 115, 116
clinical manifestations
adrenergic symptoms 117
neuroglycopenic symptoms 117, 118
overview 116, 117
definition 111
diagnosis 111, 119–121
glucose counterregulation and hormones 112, 113
infants 111
insulin induction 118, 119
sulfonylurea induction 118, 119
treatment
diabetic patients 121, 122
insulina and extrapancreatic tumor patients 123
intolerance patients 123, 124
prevention 123, 124
Imipramine, neuropathy treatment 206
Impaired glucose tolerance, conversion to diabetes 15
Insulin
c Dose-response curve 39
metabolic effects, overview 40, 41, 43
secretion process 20
secretion regulation
acetylcholine 24
cholecystokinin 24
epinephrine 24
free fatty acids 22, 28
gastric inhibitory polypeptide 24
Insulin, secretion regulation (continued)
glucagon 24, 25
glucagon-like peptide-1 24, 28, 36
glucose 20–22
leptin 25
neuropeptide Y 24
norepinephrine 24
vasoactive intestinal polypeptide 24
sulfonylurea effects on secretion
acute effects 32, 33
chronic effects 33
testing
acute insulin response
glucose 25
non-glucose stimuli 25, 26
fasting insulin level 25
type 2 diabetes 26, 27
Insulin receptor
defects in insulin resistance 44
density 38, 39
fate of ligand complexes 39, 40
isoforms 40
phosphorylation 40, 44
structure 38
Insulin resistance
drug therapy
metformin 51–53
thiazolidinediones 53, 54
trandolapril 54
verapamil 54
sites of resistance 43
syndrome of immunologic insulin resistance 86, 87
type 1 diabetes 50
type 2 diabetes
blood flow role 49, 50
counterregulatory hormones 48
free fatty acid, glucose metabolism 46–48
genetic factors 46
insulin receptor defects 44
leptin role 49
metabolic steps resistant to insulin 45
tumor necrosis factor-α role 48, 49, 55
Insulin therapy
altered response conditions 87, 88
complications
allergy 87
edema 85
lipatroph 85, 86
lipohypertrrophy 86
syndrome of immunologic insulin resistance 86, 87
education of patients 88
factors influencing concentration or bioavailability
administration routes and injection site 76, 77
antibodies 78
degradation 78
dose and concentration 76
exercise and stress 78
injection depth and massage 77, 78
mixtures of insulin 76
pharmacokinetics 76
storage of preparations 78
gestational diabetes mellitus management 244, 246, 252
hyperglycemia control benefits 231
hypoglycemia induction 118, 119
indications 72, 73
insulin characteristics
analogs 74, 75
concentration of preparations 75
duration of action 73, 74
purity 73
types 72, 73
monitoring
fructosamine 84
HBA1c 84
self-monitoring
blood glucose 84
urine tests 83
regimens
continuous subcutaneous insulin infusion 82, 83
multiple daily injection 80–82
single daily injection 79, 80
twice daily injection 80
requirements and dose 78, 79
sulfonylurea combination therapy 94
Insulin-dependent diabetes mellitus,
see Type 1 diabetes

Subject Index

260
Insulin-like growth factor I, diabetes therapy 101
Intrauterine growth restriction, diabetes 248
Intravenous glucose tolerance test, diabetes diagnosis 18, 27
Islet transplantation, type 1 diabetes 99
Ketoacidosis, see Diabetic ketoacidosis

Leprechaunism syndrome, diabetes association 12
Leptin
insulin resistance role 49
insulin secretion regulation 25
Lipoatrophy, insulin therapy reaction 85, 86
Lipodystrophy, diabetes association 12
Lipohypertrophy, insulin therapy reaction 86
Low-density lipoprotein diabetes mellitus abnormalities overview 178
type 1 diabetes 178, 179
type 2 diabetes 179–181
lipid-lowering intervention in diabetes cardiovascular disease effects 181, 182
dietary modification 182
drug therapy
fibrates 182–184
statins 182–184
guidelines for treatment 182, 184
normal metabolism 174–178

Macrosomia, fetal 248
Maggot therapy, foot ulcer treatment 215
Maturity-onset diabetes of the young clinical presentation 10, 11
prevalence 10
types and genes
familial hyperinsulinemia 11
MODY-1 10
MODY-2 10, 11, 22
MODY-3 11
Metformin
dose 53
hyperglycemia control benefits 230, 231
insulin resistance treatment 51–53
pharmacology 51, 52

side effects 52, 53
sulfonylurea combination therapy 94
Microalbuminuria, see Diabetic nephropathy
Miglitol, diabetes therapy 99
Multifactorial intervention, diabetes side effects 239, 240
treatment approach and effects 239
Myocardial infarction
diabetes association and presentation 188, 189
management in diabetes
angiotensin-converting enzyme inhibitors 193, 194
aspirin 192, 193
β-blockers 193
calcium channel blockers 194
fibrinolytic agents 192
insulin-glucose infusion 191, 192
platelet inhibitors 193
statins 194
Myocardial ischemia, treatment in diabetes 194, 195
Nephropathy, see Diabetic nephropathy
Neuropathy, see Diabetic neuropathy
Neuropeptide Y, insulin secretion regulation 24
Nicotinamide, diabetes therapy 101
Nitric oxide synthase, diabetic nephropathy role 131
Nitroglycerin, erectile dysfunction treatment 226
Noninsulin-dependent diabetes mellitus, see Type 2 diabetes
Norepinephrine, insulin secretion regulation 24

Oral glucose tolerance test diabetes diagnosis 14, 15, 26, 27
indications 16
insulin determinations 18
reliability 16
variables affecting results
age 17
blood collection site 16
diet 17
glucose dose and concentration 17
Oral glucose tolerance test, variables affecting results (continued)
  glycemia determination method 17
  illness 17
  physical activity 17
  timing of samples 17
  whole blood vs plasma or serum 16, 17
Orlistat, obese diabetes treatment 95
Pancreas transplantation, type 1 diabetes 98, 99
PC-1, insulin resistance role 44
Pineal hypertrophy syndrome, diabetes association 12
Platelet inhibitors, myocardial infarction management in diabetes 193
Platelet-derived growth factor, foot ulcer treatment 215
Pramlintide
diabetes therapy 96
  physiological actions 95, 96
Protein, dietary 63, 64, 157, 168
Protein kinase C, diabetic nephropathy role acute 32, 33
  chronic 33
  proliferative diabetic retinopathy 147, 148
  revascularization, diabetic retinopathy 54
Saccharin, safety 67, 68
Sildenafil, erectile dysfunction treatment 226, 227
Smoking, cessation effects in diabetes 238, 239
Sodium, dietary restriction 66
Somatostatin, diabetes therapy 95
Statins
dyslipidemia treatment 236
  lipid-lowering intervention 182-184
  myocardial infarction management in diabetes 194
Sulfonylureas, see also specific drugs
  combination therapy
    insulin 94
    metformin 94
doses 30
efficacy and interactions 32
extrapancreatic effects 34
failure
  primary 93
  secondary 93, 94
first-generation drugs 30, 31
history of development 29, 30
hyperglycemia control benefits 230, 231
hypoglycemia induction 118, 119
indications and contraindications 29
insulin secretion effects
  acute 32, 33
  chronic 33
proinsulin synthesis effects 34
second-generation drugs 31, 32
side effects 35
Sweeteners, diabetic diet 66-68
Thiazolidinediones, insulin resistance therapy 53, 54, 95
Tolazamide, characteristics 30
Tramadol, neuropathy treatment 206
Trandolapril, insulin resistance therapy 54
Transforming growth factor-β, diabetic nephropathy role 132
Tumor necrosis factor-β, insulin resistance role 48, 49, 55
Type 1 diabetes
classification and diagnostic groups
  3, 4, 13, 14
diagnosis 18, 19
idiopathic disease 6
immune-mediated disease
  autoimmune pathogenesis 5, 6
  clinical presentation 6
cow's milk role 5
genetic predisposition and candidate characteristics 26, 27
prevalence 4
viral infection role 5
insulin resistance 50
pathophysiology 6, 7
treatment, see also Insulin therapy autoantigen therapy 98
gene therapy 98
immunoregulatory therapy 97
immunosuppression therapy 98
islet transplantation 99
pancreas transplantation 98, 99
Type 2 diabetes, see also Gestational diabetes mellitus, Maturity-onset diabetes of the young
classification and diagnostic groups 3, 4, 13, 14
complications 9
diagnosis 19, 26, 27
diet modification, see Diet
genetic predisposition 9, 27
hyperglycemia control 9
insulin resistance
blood flow role 49, 50
counterregulatory hormones 48
free fatty acid and glucose metabolism 46–48
hyperglycemia concept 28
leptin role 49
metabolic steps resistant to insulin 45
metabolic syndrome of diabetes 45
insulin secretion of defect 27, 28
pathophysiology 9, 10
pharmacotherapy indications 92, 93
ulcer, see Foot problems, diabetes
United Kingdom Prospective Diabetes Study, outcomes of hyperglycemia and blood pressure control 91, 92, 169, 229–231
unstable angina, diabetes association and presentation 190
Vasoactive intestinal polypeptide, insulin secretion regulation 24
Verapamil, insulin resistance therapy 54
very low-density lipoprotein diabetes mellitus abnormalities
overview 178
type 1 diabetes 178, 179
type 2 diabetes 179–181
lipid-lowering intervention in diabetes cardiovascular disease effects 181, 182
dietary modification 182
drug therapy
fibates 182–184
statins 182–184
guidelines for treatment 182, 184
normal metabolism 174–178
Viagra, see Sildenafil
Vitrectomy, retinopathy treatment 149
Waist-to-hip ratio, cardiovascular risk 58
Werner’s syndrome, diabetes association 12
Yohimbine, erectile dysfunction treatment 225, 226